Related Experiment Video
Updated: Feb 8, 2026

Author Spotlight: Investigating the Mechanisms and Inducing Models of Polycystic Ovary Syndrome
Published on: July 5, 2024
Monoamine system disruption induces functional somatic syndromes associated symptomatology in mice
Yukinori Nagakura1, Nana Ohsaka2, Ryutarou Azuma2
1Faculty of Pharmaceutical Sciences, Aomori University, 2-3-1 Kohbata, Aomori-shi, Aomori 030-0943, Japan; Center for Brain and Health Sciences, Aomori University, 109-1 Takama, Ishie, Aomori-shi, Aomori 038-0003, Japan.
Abstract:
Functional somatic syndromes (FSS), a clinical condition manifesting a variety of unexplained somatic symptoms, has been proposed as an inclusive nosology encompassing individual syndromes such as fibromyalgia syndrome and irritable bowel syndrome. Accumulating evidence suggests that disturbance of the endogenous monoamine system could be involved in the aetiology of FSS. Therefore, the purpose of present study was to investigate whether the disturbance of the monoamine system would cause FSS-associated symptomatology in mice. The optimal dose of reserpine, an inducer of endogenous monoamines reduction, was first explored in mice. General body condition (body weight, rectal temperature, and ptosis) and FSS-associated symptomatology (paw withdrawal threshold, small intestinal transit, and locomotor activity) were measured. The concentration of monoamines was measured in central and peripheral tissues. Mice dosed with reserpine (0.25 mg/kg s.c., once daily for 3 consecutive days) exhibited a decrease in paw withdrawal threshold, delay in small intestinal transit, and reduction of locomotor activity without deterioration of general body condition on day 5 after the first reserpine injection. The concentration of monoamines was decreased in the central nervous system and skeletal muscle, but not in the small intestine. A reserpine dose of 0.5 mg/kg or more caused deterioration of general body condition. In conclusion, the optimal protocol of reserpine treatment for inducing pain symptom without deterioration of general physical condition is 0.25 mg/kg s.c., once daily for 3 consecutive days in mice. This protocol causes not only pain but also FSS-associated symptomatology which are associated with disruption of the endogenous monoamine system. The reserpine-treated animal may be useful for the research of not only fibromyalgia syndrome but also FSS, especially for the research focusing on the hypothesis that FSS is associated with the disturbance of endogenous monoamine system.
Insights
Reserpine treatment in mice effectively models functional somatic syndromes (FSS) by inducing pain and other symptoms. This model, linked to monoamine system disruption, is valuable for FSS research, including fibromyalgia.
Area of Science:
- Neuroscience
- Pharmacology
- Medical Research
Background:
- Functional somatic syndromes (FSS) encompass conditions like fibromyalgia and irritable bowel syndrome, characterized by unexplained somatic symptoms.
- Evidence suggests a link between endogenous monoamine system disturbances and the etiology of FSS.
Purpose of the Study:
- To investigate if disrupting the monoamine system in mice can induce FSS-associated symptomatology.
- To determine the optimal reserpine dosage for inducing FSS symptoms without compromising general body condition.
Main Methods:
- Exploration of optimal reserpine doses in mice to induce endogenous monoamine reduction.
- Measurement of general body condition (body weight, rectal temperature, ptosis) and FSS-associated symptoms (paw withdrawal threshold, intestinal transit, locomotor activity).
- Quantification of monoamine concentrations in central and peripheral tissues.
Main Results:
- A reserpine dose of 0.25 mg/kg/day for 3 days induced decreased paw withdrawal threshold, delayed intestinal transit, and reduced locomotor activity.
- This optimal dose did not cause deterioration in general body condition.
- Monoamine concentrations were reduced in the central nervous system and skeletal muscle, but not the small intestine.
Conclusions:
- The optimal reserpine protocol (0.25 mg/kg/day for 3 days) effectively induces pain and FSS-associated symptoms in mice.
- These induced symptoms are linked to disruptions in the endogenous monoamine system.
- The reserpine-treated mouse model is a valuable tool for researching FSS, particularly the hypothesis involving monoamine system disturbances.
More Related Videos
13:34Assessment of Memory Function in Pilocarpine-induced Epileptic Mice
Published on: June 4, 2020
09:39Generation of Induced Pluripotent Stem Cells from Turner Syndrome 45XO Fetal Cells for Downstream Modelling of Neurological Deficits Associated with the Syndrome
Published on: December 4, 2021
Related Concept Videos
Somatic Spinal Reflexes
One of the most well-known somatic spinal reflexes is the stretch reflex, which is activated by the sudden stretching of a muscle. This reflex involves the activation of specialized sensory receptors called muscle spindles, which are located in the muscle tissue and detect changes in the length and speed of muscle contractions. When a muscle is suddenly...
Overview of Somatic Sensory Pathways
The somatosensory system is divided into three main pathways: the dorsal (or posterior) column-medial lemniscus, spinothalamic (or anterolateral), and spinocerebellar pathways.
The dorsal...
Somatic to iPS Cell Reprogramming
Major Somatic Sensory Pathways
Nephrotic Syndrome I : Introduction
Acute Coronary Syndrome I: Introduction